Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study

INTRODUCTION: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used as the first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC). Nevertheless, most cases ultimately acquire resistance to osimertinib, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Kageaki, Yoh, Kiyotaka, Hosomi, Yukio, Usui, Kazuhiro, Naka, Go, Kishi, Kazuma, Uemura, Kohei, Ohashi, Yasuo, Kunitoh, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728446/
https://www.ncbi.nlm.nih.gov/pubmed/34983748
http://dx.doi.org/10.1136/bmjopen-2020-046451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728446/
https://www.ncbi.nlm.nih.gov/pubmed/34983748
http://dx.doi.org/10.1136/bmjopen-2020-046451

Ejemplares similares